40 trials changed in the last 30 days: 0 stopped, 25 with notable changes, 15 with minor changes only.
Primary completion pushed from Jan 10, 2028 to Jan 9, 2029
Also in this update: Enrollment reduced: 451 → 346 participants; Interventions modified
GlaxoSmithKlinePhase 1/2 NCT06885034 Registry history of NCT06885034 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 17, 2029 to Jul 22, 2030
And 1 more change in the last 30 days
GlaxoSmithKlinePhase 3 NCT07286266 Registry history of NCT07286266 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from May 25, 2026 to May 14, 2027
GlaxoSmithKlinePhase 3 NCT06666491 Registry history of NCT06666491 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 22, 2026 to May 20, 2027
Also in this update: Recruitment opened
GlaxoSmithKlinePhase 1 NCT07600450 Registry history of NCT07600450 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jul 13, 2026 to Feb 14, 2028
Also in this update: Trial sites expanded: 6 → 22 locations; Study completion pushed from Sep 29, 2028 to May 1, 2030
GlaxoSmithKlinePhase 1 NCT07277270 Registry history of NCT07277270 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Oct 6, 2026; Study completion pushed from Mar 31, 2027 to Jun 14, 2027
GlaxoSmithKlinePhase 4 NCT06372496 Registry history of NCT06372496 on ClinicalTrials.gov (opens the registry)
Enrollment reduced: 292 → 138 participants
GlaxoSmithKlinePhase 3 NCT05757102 Registry history of NCT05757102 on ClinicalTrials.gov (opens the registry)
Enrollment reduced: 113 → 64 participants
Also in this update: Trial sites expanded: 6 → 13 locations
GlaxoSmithKlinePhase 1/2 NCT07602777 Registry history of NCT07602777 on ClinicalTrials.gov (opens the registry)
Phase changed: Phase 1/2 → Phase 3
GlaxoSmithKlinePhase 3 NCT07860450 Registry history of NCT07860450 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 8 locations; Start date changed from estimate of Sep 3, 2026 to Sep 24, 2026
GlaxoSmithKlinePhase 3 NCT07684599 Registry history of NCT07684599 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 3 locations
GlaxoSmithKlinePhase 3 NCT07782970 Registry history of NCT07782970 on ClinicalTrials.gov (opens the registry)
Sponsor changed: Scynexis, Inc. to GlaxoSmithKline
Also in this update: Primary and study completion moved earlier from Oct 31, 2029 to Jul 31, 2029
GlaxoSmithKlineNot specified NCT05908682 Registry history of NCT05908682 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 12 locations
GlaxoSmithKlinePhase 3 NCT07851246 Registry history of NCT07851246 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 5 locations; Start date changed from estimate of Sep 22, 2026 to Sep 1, 2026
GlaxoSmithKlinePhase 3 NCT07802704 Registry history of NCT07802704 on ClinicalTrials.gov (opens the registry)
Recruitment opened
GlaxoSmithKlinePhase 3 NCT07782996 Registry history of NCT07782996 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 1 → 8 locations; Start date changed from estimate of Sep 22, 2026 to Sep 8, 2026
GlaxoSmithKlinePhase 3 NCT07684612 Registry history of NCT07684612 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 4 locations
GlaxoSmithKlinePhase 3 NCT07780656 Registry history of NCT07780656 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 15 locations; and 1 more change in the last 30 days
GlaxoSmithKlinePhase 3 NCT07645248 Registry history of NCT07645248 on ClinicalTrials.gov (opens the registry)
Recruitment opened
GlaxoSmithKlinePhase 3 NCT07780643 Registry history of NCT07780643 on ClinicalTrials.gov (opens the registry)
Recruitment opened
And 1 more change in the last 30 days
GlaxoSmithKlinePhase 3 NCT07782957 Registry history of NCT07782957 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 93 → 60 locations
GlaxoSmithKlinePhase 3 NCT05334368 Registry history of NCT05334368 on ClinicalTrials.gov (opens the registry)
Trial completed
GlaxoSmithKlinePhase 1 NCT07670377 Registry history of NCT07670377 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
GlaxoSmithKlinePhase 1 NCT07406334 Registry history of NCT07406334 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 20 → 25 participants
Also in this update: Trial sites expanded: 0 → 4 locations
GlaxoSmithKlinePhase 1 NCT07371429 Registry history of NCT07371429 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 58 → 72 locations
And 1 more change in the last 30 days
GlaxoSmithKlinePhase 3 NCT07585266 Registry history of NCT07585266 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 15 → 281 locations
Also in this update: Interventions modified; Study completion moved earlier from Aug 20, 2029 to Feb 14, 2029
GlaxoSmithKlinePhase 3 NCT06959095 Registry history of NCT06959095 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 159 → 193 locations
Also in this update: Interventions modified; Study completion moved earlier from Aug 21, 2029 to Feb 14, 2029
GlaxoSmithKlinePhase 3 NCT06961214 Registry history of NCT06961214 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 28 → 48 locations
GlaxoSmithKlinePhase 3 NCT07286331 Registry history of NCT07286331 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 7 → 15 locations
GlaxoSmithKlinePhase 3 NCT07701993 Registry history of NCT07701993 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 12 → 20 locations
GlaxoSmithKlinePhase 3 NCT07704892 Registry history of NCT07704892 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 6 → 30 locations
GlaxoSmithKlinePhase 2 NCT05087056 Registry history of NCT05087056 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 110 → 114 locations
GlaxoSmithKlinePhase 2 NCT07519395 Registry history of NCT07519395 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 16 → 20 locations
GlaxoSmithKlinePhase 1 NCT07438782 Registry history of NCT07438782 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Aug 31, 2027 to Jun 30, 2026
GlaxoSmithKlinePhase 1 NCT05277051 Registry history of NCT05277051 on ClinicalTrials.gov (opens the registry)
Interventions modified
GlaxoSmithKlinePhase 3 NCT07099898 Registry history of NCT07099898 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-13 | NCT07872046 A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular… | Phase 3 | Not Yet Recruiting |
| 2026-10-09 | NCT07867171 A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on… | Phase 1 | Not Yet Recruiting |
| 2026-10-07 | NCT07862114 A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy… | Phase 1 | Not Yet Recruiting |
| 2026-10-06 | NCT07859735 A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib | Phase 1 | Not Yet Recruiting |
| 2026-10-06 | NCT07860450 Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel… | Phase 3 | Not Yet Recruiting |
| 2026-10-06 | NCT07860710 J-LINX: Japan LINerixibat eXtension Study | Phase 3 | Not Yet Recruiting |
| 2026-10-01 | NCT07851246 A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in… | Phase 3 | Recruiting |
| 2026-09-30 | NCT07850141 Prospective Registry of Exposure to Gepotidacin (PREG) | Not Yet Recruiting | |
| 2026-09-28 | NCT07843641 A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST) | Phase 2 | Not Yet Recruiting |
| Phase 1 | 36 | |
| Phase 1/2 | 21 | |
| Phase 2 | 35 | |
| Phase 2/3 | 3 | |
| Phase 3 | 62 | |
| Phase 4 | 9 |
Multiple Myeloma (20) · Asthma (12) · Colorectal Cancer (10) · Endometrial Cancer (10) · COPD (7) · NASH / MASH (7) · Lung Cancer (6) · Lupus (SLE) (5) · Ovarian Cancer (5) · Non-Small Cell Lung Cancer (NSCLC) (4)